FindTrial
Sign In

Nutritional support study of compound small molecule peptides for multiple myeloma chemotherapy patients

Exploration of the Application of Complex Small Molecule Peptides in Nutritional Support for Patients with Multiple Myeloma undergoing Chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128101
Enrollment
Unknown
Registered
2026-07-14
Start date
2026-07-14
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Control group (conventional chemotherapy care + basic nutritional support):None
Compound small peptide supplement group:None

Sponsors

Wuxi people’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for multiple myeloma (MM) in the "Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2024 Edition)" and receive standard chemotherapy regimens; 2. Age >=18 years old; 3. Complete clinical data; 4. Expected survival period: >=6 months; 5. Karnofsky Performance Status Score (KPS) >=65 points (i.e., basically self-sufficient in daily life and able to tolerate chemotherapy); 6. No other special nutritional supplement treatment has been received within one month before chemotherapy. 7. There was no history of serious infection or gastrointestinal diseases within one month before chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Combined with severe liver and kidney failure, heart failure, coagulation dysfunction, etc. 2. Allergy to the ingredients of complex small molecule peptide supplements; 3. Combined with other malignant tumors; 4. Have mental illness or cognitive impairment and be unable to cooperate in completing the research; 5. Participate in other clinical trials within one month before screening; 6. The researcher believes that the compliance is poor, or the researcher believes that the subject has any other circumstances that make it unsuitable to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Core indicators of protein nutritional status - prealbumin (PAB), total protein (TP), albumin (ALB), hemoglobin (Hb);—

Secondary

MeasureTime frame
Immune function indicators (IgA, IgM, IgG, CD4? /CD8? ratio);Nutritional Prognostic Index (assessment of nutritional status using the Patient-Generated Subjective Global Assessment, PG-SGA);KPS Score;Disease classification;Chemotherapy toxicities and adverse reactions;Inflammatory indicators (CRP, IL-6, TNF-a);—

Countries

China

Contacts

Public ContactZhou Quyan

Wuxi people’s Hospital

qunyan224@163.com+86 13358111996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026